Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Sanofi’s Praluent to Be Taken Off Japan NHI Price List Next Spring
November 26, 2021
- Medical Fee, Drug Price Revisions Major Topics for FY2022 Budget: MHLW
November 25, 2021
- LDP Health Panel Chief Vows to Push Development of Japan-Made Vaccines and Drugs
November 25, 2021
- 1st Lucentis Biosimilar, 3rd Humira Follow-On Get Japan Listing
November 24, 2021
- BMS’ Second CAR-T Therapy Ide-Cel Up for PAFSC Review on Dec. 6
November 24, 2021
- Orphan Status Granted to Daiichi Sankyo’s Valemetostat Tosilate, 2 Other APIs
November 24, 2021
- Japan OKs 56 Trillion Yen Stimulus Package, Spells Out Support for Japan-Made Drugs and Vaccines
November 22, 2021
- Amitiza Gets Label Update for Opioid-Induced Constipation
November 22, 2021
- Japan to Go Ahead with Procedures for Pediatric Vaccination without Preconceptions: Minister
November 22, 2021
- Japan Sets Up Vaccine Team Confab of Sr. Vice Ministers
November 22, 2021
- Amgen’s KRAS Inhibitor, MSD’s Cough Drug Up for PAFSC Review on Dec. 2
November 19, 2021
- Japan Panel Discusses Safety, Immunity Rules for Envisaged Emergency Approval Scheme
November 19, 2021
- Japan Looks to Start Pediatric COVID-19 Vaccinations from February
November 19, 2021
- Ex-Minister Tamura Says Efficacy/Safety Confirmation Important in Emergency Approval, Wary on Macroeconomic Indexing
November 18, 2021
- Chuikyo Calls for Smooth Transition to Fertility Treatment Coverage from Current Subsidy System
November 18, 2021
- Vynmac Listing OK’ed, but Chuikyo Urges Response to Market Expansion with Similar Upgrade
November 18, 2021
- Health Minister Stresses Basic 8-Month Interval for Booster Shot
November 17, 2021
- November Listing OK’ed for Cibinqo, Retevmo, Padcev and More
November 17, 2021
- MHLW Panel to Discuss Idorsia’s Cerebral Vasospasm Drug on Nov. 26; Efient Up for Review Again
November 17, 2021
- Sclerosing Cholangitis Added to ADR List in Tecentriq Label
November 17, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…